Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic launch plans

Af­ter near­ly two decades as of­ten one of the on­ly com­pa­nies de­vel­op­ing off-the-shelf CAR-Ts, Cel­lec­tis has in re­cent years racked up big-name part­ner­ships, in­clud­ing with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.